When it comes to getting shots, less is more, especially if you’re a kid. Thankfully, Sanofi and Merck worked together to develop a new 6-in-1 vaccine that protects against a variety of diseases and greatly reduces the number of shots a kid has to sustain. According to a December 28th Forbes article, Vaxelis is a hexavalent vaccine that offers protection against diphtheria, tetanus, pertussis, hepatitis B, polio, and invasive haemophilus influenza type B disease.
Vaxelis was approved in the EU three years ago and reached market in early 2016, and it was the third hexavalent vaccine to do so. Sanofi and Merck likely won’t have the Vaxelis production lines in place to offer the vaccine to a wide audience until 2020 at the earliest.